These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35976570)

  • 1. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
    Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
    Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
    Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
    Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
    Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
    N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
    Usansky H; Yoon E; Teper A; Zou J; Fernandez C
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):832-842. PubMed ID: 35411669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
    Basso J; Chen KJ; Zhou Y; Mark L; LaSala D; Dorfman A; Atalla M; Chun D; Viramontes V; Chang C; Leifer F; McDonald PP; Cipolla DC
    Front Pharmacol; 2023; 14():1208780. PubMed ID: 37538173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis.
    Gunsolley JC; Chalmers JD; Sibila O; Fernandez C; Scannapieco FA
    JDR Clin Trans Res; 2024 Jul; 9(3):277-285. PubMed ID: 37746735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
    Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
    Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.
    Palmér R; Mäenpää J; Jauhiainen A; Larsson B; Mo J; Russell M; Root J; Prothon S; Chialda L; Forte P; Egelrud T; Stenvall K; Gardiner P
    Clin Pharmacol Ther; 2018 Dec; 104(6):1155-1164. PubMed ID: 29484635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target.
    Mall MA; Davies JC; Donaldson SH; Jain R; Chalmers JD; Shteinberg M
    Eur Respir Rev; 2024 Jul; 33(173):. PubMed ID: 39293854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
    McDonald PP; Leifer FG; Basso J; Lasala D; Li D; Chen KJ; Zhang J; Perkins WR; Cipolla DC
    Front Immunol; 2023; 14():1231047. PubMed ID: 37638021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.
    Chalmers JD; Burgel PR; Daley CL; De Soyza A; Haworth CS; Mauger D; Mange K; Teper A; Fernandez C; Conroy D; Metersky M
    ERJ Open Res; 2024 Jul; 10(4):. PubMed ID: 39040578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.
    Watz H; Nagelschmitz J; Kirsten A; Pedersen F; van der Mey D; Schwers S; Bandel TJ; Rabe KF
    Pulm Pharmacol Ther; 2019 Jun; 56():86-93. PubMed ID: 30917927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.
    Keir HR; Long MB; Abo-Leyah H; Giam YH; Vadiveloo T; Pembridge T; Hull RC; Delgado L; Band M; McLaren-Neil F; Adamson S; Lahnsteiner E; Gilmour A; Hughes C; New BJ; Connell D; Dowey R; Turton H; Richardson H; Cassidy D; Cooper J; Suntharalingam J; Diwakar L; Russell P; Underwood J; Hicks A; Dosanjh DP; Sage B; Dhasmana D; Spears M; Thompson AR; Brightling C; Smith A; Patel M; George J; Condliffe AM; Shoemark A; MacLennan G; Chalmers JD;
    Lancet Respir Med; 2022 Dec; 10(12):1119-1128. PubMed ID: 36075243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.
    Stick SM; Foti A; Ware RS; Tiddens HAWM; Clements BS; Armstrong DS; Selvadurai H; Tai A; Cooper PJ; Byrnes CA; Belessis Y; Wainwright C; Jaffe A; Robinson P; Saiman L; Sly PD;
    Lancet Respir Med; 2022 Aug; 10(8):776-784. PubMed ID: 35662406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Neutrophil Elastase and Cathepsin G Activity in Human Sputum Samples.
    Frey DL; Guerra M; Mall MA; Schultz C
    J Vis Exp; 2021 May; (171):. PubMed ID: 34096915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
    Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
    Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum.
    Dubois AV; Gauthier A; Bréa D; Varaigne F; Diot P; Gauthier F; Attucci S
    Am J Respir Cell Mol Biol; 2012 Jul; 47(1):80-6. PubMed ID: 22343221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis.
    Attucci S; Gauthier A; Korkmaz B; Delépine P; Martino MF; Saudubray F; Diot P; Gauthier F
    J Pharmacol Exp Ther; 2006 Aug; 318(2):803-9. PubMed ID: 16627747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.
    Chalmers JD; Moffitt KL; Suarez-Cuartin G; Sibila O; Finch S; Furrie E; Dicker A; Wrobel K; Elborn JS; Walker B; Martin SL; Marshall SE; Huang JT; Fardon TC
    Am J Respir Crit Care Med; 2017 May; 195(10):1384-1393. PubMed ID: 27911604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.
    Craciun I; Fenner AM; Kerns RJ
    Glycobiology; 2016 Jul; 26(7):701-709. PubMed ID: 26850997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.